Drug Trial Radar · NCT07859839
Gabapentin vs. Benzonatate vs. Standard of Care for Cough in ILD
Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
177
Planned (sponsor's estimate)
Start
Oct 7, 2026
Primary completion
Jun 30, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Absence of a clear standard of care and approved drug for chronic cough, the commonest symptom in ILD, calls for further research in this area. In this study, the investigators aim to compare gabapentin and benzonatate treatment with the standard of care for treating chronic cough in ILD. The investigators hypothesize that both gabapentin and benzonatate will be more effective than standard of care in treating chronic cough in ILD.
Conditions
- Interstitial Lung Disease
Interventions
GabapentinDrug
Gabapentin at starting dose of 100 mg per dose, thrice daily and up titrated by 100 mg per dose every 3 days till 300 mg per dose, thrice daily or maximum tolerated dose
Benzonatate 200 mgDrug
Benzonatate at starting dose of 100 mg per dose thrice daily and up titrated to 200 mg per dose thrice daily after 3 days
Standard of care treatment for ILDOther
Standard Therapy including immunosuppressive and/or anti-fibrotic agent/s and symptomatic therapy for cough (as needed dextromethorphan lozenges)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cough intensity in Gabapentin groupTime frame: 8 weeks
- Cough intensity in benzonatate armTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Postgraduate Institute of Medical Education and Research
Chandigarh, Chandigarh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.